Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding about 1.4%.
The iShares Biotechnology ETF (IBB) gained almost 2%.
In corporate news, CVS Health (CVS) put in a bid for a number of Rite Aid stores in Washington, Oregon and Idaho, as well as patient prescription data, Bloomberg reported, citing a recording of a meeting between Rite Aid Chief Executive Matthew Schroeder and employees. CVS shares added 0.7%.
Incyte (INCY) shares rose 2.6% after the firm said the US Food and Drug Administration has approved Zynyz for the treatment of advanced squamous cell carcinoma of the anal canal in combination with chemotherapy and as a monotherapy.
Immutep (IMMP) shares jumped 8.2%. The company said its investigational drug, eftilagimod alpha, combined with Merck's (MRK) Keytruda and doublet chemotherapy achieved a response rate of 60.8% and disease control rate of 90.2% in people with non-small cell lung cancer in an investigator-initiated trial.
UnitedHealth Group (UNH) responded Wednesday to a Wall Street Journal report about a US Department of Justice criminal investigation linked to itss Medicare Advantage program. The company said it has not received any notification from the DOJ and described the WSJ report, without official attribution, as "deeply irresponsible." UnitedHealth shares were falling 11%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。